ForSight Robotics Secures $125M to Advance Robotic Cataract Surgery and Transform Ophthalmology

Robotic surgery in ophthalmology is taking a giant leap forward. ForSight Robotics has announced a $125 million Series B funding round, led by Eclipse and Adani group, to accelerate the development of its ORYOM robotic surgical platform. This brings the company's total funding to $195 million, marking one of the largest venture capital investments in ophthalmic medical technology to date.

With global demand for cataract surgery and glaucoma treatment rapidly increasing—and a shortage of trained ophthalmologists—ForSight’s robotic solution aims to revolutionise how eye diseases are treated, helping to prevent blindness and improve access to high-precision care.

Solving the Global Cataract and Glaucoma Crisis with Robotics

More than 600 million people worldwide suffer from cataracts, yet only a fraction receive timely surgery. Glaucoma, a leading cause of irreversible blindness, affects over 76 million people and is projected to impact even more as populations age. Meanwhile, the number of ophthalmologists able to perform these delicate procedures is not keeping pace with demand.

ForSight Robotics’ response is the ORYOM Platform, a first-of-its-kind robotic surgery system designed specifically for ophthalmology. Meaning “daylight” in Hebrew, ORYOM provides AI-powered precision, enabling consistent outcomes in cataract surgery and future expansion into glaucoma surgery and retinal procedures.

ORYOM: A Robotic Surgery Platform Built for the Eye

ORYOM is engineered for the unique challenges of eye surgery, offering:

• 14 degrees of freedom to navigate complex ocular anatomy

• AI-based algorithms and computer vision to optimise micro-movements

• Access to both anterior and posterior segments of the eye—ideal for cataracts, glaucoma, and retinal interventions

• Enhanced ergonomics to reduce surgeon fatigue and musculoskeletal strain—critical given that over 60% of ophthalmologists report occupational discomfort

To date, over two dozen leading ophthalmic surgeons have successfully performed hundreds of procedures on animal eye models using ORYOM, validating its safety, precision, and user experience.

A New Era in Ophthalmic Robotics: From Cataracts to Glaucoma

While ORYOM will debut with robotic cataract surgery, the platform’s design allows for future applications in glaucoma surgery, retinal procedures, and potentially corneal transplants. This is a transformative moment not only for eye surgeons, but for patients at risk of vision loss or blindness due to delayed care.

Dr. Joseph Nathan, co-founder and Chief Medical Officer of ForSight Robotics, explains:

“We see ophthalmology as the next frontier in the robotics revolution—much like general surgery before the rise of Intuitive Surgical. With a comparable market size and urgent global need, our opportunity is immense.”

Backed by Leading Venture Capital and Industry Pioneers

The $125M Series B round was led by Eclipse, a top-tier venture capital firm focused on transformative technologies. Other major contributors include:

• A strategic (undisclosed) MedTech investor

• Adani Group

• Reiya Ventures

• Dr. Frederic Moll, renowned for co-founding Intuitive Surgical and Auris Health

These investors bring both capital and strategic insight, especially as ForSight prepares for first-in-human clinical trials later this year.

Momentum, Growth, and Milestones

In the past 12 months, ForSight Robotics has:

• Doubled its team to more than 110 employees

• Expanded its executive and engineering teams

• Achieved ISO 13485:2016 certification, the global benchmark for medical device safety and quality

• Advanced preparations for clinical trials in robotic cataract surgery

With these milestones, ForSight is poised to bring ORYOM from preclinical validation to regulatory approval and clinical adoption.

Why Robotic Eye Surgery Matters for Global Ophthalmology

The World Health Organization has declared avoidable blindness a global health priority. Robotic platforms like ORYOM could help close the treatment gap by:

• Standardising cataract and glaucoma surgeries, reducing complications

• Extending access to high-quality eye care in underserved regions

• Easing the physical demands on eye surgeons

• Reducing patient wait times and improving long-term visual outcomes

This aligns with RatedDoctor.com’s mission to promote innovations that empower clinicians, increase access to care, and improve patient outcomes.

Implications for Ophthalmologists and Hospitals

For practising ophthalmologists, robotic platforms like ORYOM offer several benefits:

• Improved surgical precision, especially in challenging or high-volume cases

• Potential to extend surgical careers by reducing physical strain

• A tool to train junior surgeons with more controlled and repeatable outcomes

For clinics and hospitals, adopting robotic eye surgery could lead to:

• Competitive differentiation

• Increased surgical throughput

• Data-rich insights into procedural quality

It also opens up exciting possibilities for tele-robotic ophthalmology, particularly in regions facing acute shortages of skilled surgeons.

What’s Next for ForSight Robotics?

Here’s what the ophthalmology community can expect over the next 12–18 months:

1. Human clinical trials for robotic cataract surgery using ORYOM

2. Regulatory filings for CE mark and FDA approval

3. Expansion into other markets with high blindness burden

4. Research into robotic glaucoma surgery and posterior segment applications

5. Development of tele-surgical capabilities for remote interventions

Call to Action for Ophthalmologists and Eye Care Professionals

As a Trending Topic on RatedDoctor.com, we invite the ophthalmology community to follow this story and share your thoughts:

• Are you excited about the potential of robotic cataract and glaucoma surgery?

• What barriers to adoption do you foresee in your practice?

• Would robotic precision change how you manage complex cases?

Let’s start the conversation and shape the future of robotic eye surgery together.

Conclusion: A Defining Moment in Ophthalmic Surgery

With its $125 million funding round and cutting-edge ORYOM platform, ForSight Robotics is ushering in a new era of robotic precision in ophthalmology. This is not just a leap in surgical technology—it’s a strategic solution to the global shortage of ophthalmologists, the rising demand for cataract and glaucoma surgeries, and the need to reduce preventable blindness.

RatedDoctor.com will continue to track ForSight’s journey as it progresses through clinical trials, regulatory pathways, and global adoption. This is one innovation that truly puts the future of ophthalmic care in focus.

Learn More

Visit www.forsightrobotics.com for more about the ORYOM Platform.

Want to connect with forward-thinking eye surgeons or list your practice?
Join RatedDoctor.com – the home for Rated private specialists.